10,670 Shares in Verona Pharma plc (NASDAQ:VRNA) Acquired by Legato Capital Management LLC

Legato Capital Management LLC bought a new position in Verona Pharma plc (NASDAQ:VRNA) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 10,670 shares of the company’s stock, valued at approximately $154,000.

Several other institutional investors also recently bought and sold shares of VRNA. Campbell & CO Investment Adviser LLC grew its position in shares of Verona Pharma by 1.7% in the fourth quarter. Campbell & CO Investment Adviser LLC now owns 50,836 shares of the company’s stock valued at $1,011,000 after purchasing an additional 862 shares during the period. D.A. Davidson & CO. boosted its stake in Verona Pharma by 2.8% in the 4th quarter. D.A. Davidson & CO. now owns 33,400 shares of the company’s stock worth $664,000 after buying an additional 900 shares during the last quarter. 1492 Capital Management LLC grew its holdings in Verona Pharma by 1.0% in the 4th quarter. 1492 Capital Management LLC now owns 166,038 shares of the company’s stock valued at $3,301,000 after buying an additional 1,579 shares during the period. CWM LLC acquired a new position in shares of Verona Pharma during the 2nd quarter valued at about $29,000. Finally, Cape Investment Advisory Inc. acquired a new position in shares of Verona Pharma during the 4th quarter valued at about $40,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

VRNA has been the subject of a number of recent analyst reports. Canaccord Genuity Group boosted their target price on shares of Verona Pharma from $35.00 to $37.00 and gave the company a “buy” rating in a report on Monday, July 22nd. HC Wainwright boosted their price objective on shares of Verona Pharma from $32.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Finally, Truist Financial increased their target price on Verona Pharma from $32.00 to $38.00 and gave the stock a “buy” rating in a research report on Friday, June 28th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $36.00.

Verona Pharma Trading Up 1.7 %

VRNA stock traded up $0.46 during midday trading on Tuesday, reaching $27.15. 633,166 shares of the company’s stock traded hands, compared to its average volume of 896,779. The company has a debt-to-equity ratio of 0.72, a current ratio of 8.61 and a quick ratio of 8.61. Verona Pharma plc has a fifty-two week low of $11.39 and a fifty-two week high of $28.83. The business has a 50-day moving average price of $20.90 and a two-hundred day moving average price of $17.29. The company has a market capitalization of $2.17 billion, a P/E ratio of -34.66 and a beta of 0.44.

Verona Pharma (NASDAQ:VRNA) last posted its earnings results on Thursday, August 8th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.53). During the same quarter last year, the business posted ($0.11) EPS. Equities research analysts forecast that Verona Pharma plc will post -2.07 EPS for the current fiscal year.

Verona Pharma Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.